
|Articles|April 13, 2020
Glaucoma 360: Glaucoma devices update with Victor Chan, MB, MS (Santen Inc)
Author(s)Alex Delaney-Gesing
Advertisement
Victor Chan, MBA, MS, director of U.S. Surgical Device Commercial Marketing at Santen, Inc., offers insight on the Glaucoma Devices panel discussion regarding new innovations and diagnostic devices during Glaucoma 360 2020 in San Francisco, California.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Retina Society 2026: Medium-dose OCU410 gene therapy cuts geographic atrophy progression by up to 32% in phase 2 trial
2
Remigromig noninferior to ranibizumab in phase 2b/3 BRUNELLO DME trial
3
Retina Society 2026: MCO-010 optogenetic therapy maintains visual acuity gains through 4 years in advanced RP
4
Retina Society 2026: Ocular syphilis, HIV co-infection, and RPR titers
5










